Akebia Therapeutics (AKBA) Total Liabilities (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Total Liabilities of $335.1 million for Q1 2026, up 17.35% year-over-year from $285.6 million in Q1 2025, and down 2.56% quarter-over-quarter from $344.0 million in Q4 2025.
Akebia Therapeutics (AKBA) Total Liabilities (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Total Liabilities for 14 consecutive years, with $335.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 17.35% year-over-year to $335.1 million; the TTM figure through Mar 2026 stood at $335.1 million (up 17.35% YoY), while the FY2025 annual figure was $344.0 million, up 27.46% from the prior year.
- Total Liabilities declined to $335.1 million in Q1 2026 per AKBA's latest filing, from $344.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $519.2 million in Q1 2022 and bottomed at $252.7 million in Q1 2024.
- Historically, Total Liabilities has averaged $326.0 million across 5 years, with a median of $300.1 million in 2023.
- Annual changes were most pronounced in 2023 — Total Liabilities tumbled 42.21% — and 2025, when it grew 27.46%.
- Akebia Therapeutics' Total Liabilities stood at $350.8 million in 2022, then slipped by 22.39% to $272.3 million in 2023, then decreased by 0.89% to $269.9 million in 2024, then grew by 27.46% to $344.0 million in 2025, then fell by 2.56% to $335.1 million in 2026.
- Business Quant data shows AKBA's Total Liabilities at $335.1 million in Q1 2026, $344.0 million in Q4 2025, and $322.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.12 Bn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 324.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 324.64 Mn |
| Mar 31, 2026 | 335.15 Mn |
| Dec 31, 2025 | 343.96 Mn |
| Sep 30, 2025 | 322.56 Mn |
| Jun 30, 2025 | 316.37 Mn |
| Mar 31, 2025 | 285.60 Mn |
| Dec 31, 2024 | 269.86 Mn |
| Sep 30, 2024 | 257.54 Mn |
| Jun 30, 2024 | 253.95 Mn |
| Mar 31, 2024 | 252.74 Mn |
| Dec 31, 2023 | 272.29 Mn |
| Sep 30, 2023 | 274.42 Mn |
| Jun 30, 2023 | 280.52 Mn |
| Mar 31, 2023 | 300.05 Mn |
| Dec 31, 2022 | 350.82 Mn |
| Sep 30, 2022 | 435.99 Mn |
| Jun 30, 2022 | 470.95 Mn |
| Mar 31, 2022 | 519.22 Mn |
| Dec 31, 2021 | 455.34 Mn |
| Sep 30, 2021 | 465.12 Mn |